• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 4:19:53 PM ET
    $TLC
    Major Pharmaceuticals
    Health Care
    Get the next $TLC alert in real time by email
    SC 13G/A 1 sc_13ga.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No.1)*


    Taiwan Liposome Company, Ltd.
    (Name of the Issuer)
     
     
    Common Shares, par value NT$10 per share
    American Depository Shares each representing Two Common Shares
    (Title of Class of Securities)
     
     
    874038102
    (CUSIP Number)
     
    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☐ Rule 13d-1(c)
    ☒ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    CUSIP No. 874038102
    1.
    Name of Reporting Persons.
     
    Chang-Hai Lin

    2.
    Check the Appropriate Box if a Member of a Group (See Instruction)
     
    (a) ☐
    (b) ☒
    3.
    SEC Use Only

    4.
    Citizenship or Place of Organization
     
    Republic of China (Taiwan)
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power

    4,962,946 Common Shares
    6.
    Shared Voting Power

    N/A
    7.
    Sole Dispositive Power

    4,962,946 Common Shares
    8.
    Shared Dispositive Power

    N/A
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    4,962,946 Common Shares
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ]
    11.
    Percent of Class Represented by Amount in Row (9)
     
    5.89% of the total number of Common Shares (including the underlying shares represented by the American Depositary Shares), based on a total of 84,154,934 Common Shares of the Issuer issued and outstanding as of December 31, 2020, based on information provided by the Issuer.
    12.
    Type of Reporting Person (See Instructions)
     
    IN
     

    Item 1.
     
       
    (a)
    Name of Issuer: Taiwan Liposome Company, Ltd.
         
    (b)
    Address of Issuer’s Principal Executive Offices:
         
       
    11F-1, No. 3 Yuanqu Street
     
    Nangang District


     

    Taipei City, Taiwan 11503
     

    Republic of China
       
    Item 2.
     
       
    (a)
    Name of Person Filing:
         
        Chang-Hai Lin
         
    (b)
    Address of Principal Business Office or, if None, Residence:
         

     
    11F-1, No. 3 Yuanqu Street

     
    Nangang District

     
    Taipei City, Taiwan 11503
       
    Republic of China
         
    (c)
    Citizenship:
         

     
    Republic of China (Taiwan)
         
    (d)
    Title and Class of Securities:
         

     
    Common Shares, par value of NT$10 each.
         
    (e)
    CUSIP No.:
         

     
    874038102
         
    Item 3.
    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
         
    Not applicable.

    Item 4.
    Ownership

                  
    (c) Number of shares* as to which such person has:
                        
    (ii) Shared


                        
    power
     
    (iv) Shared
                        
    to vote

    power to
     


    or to
    (iii) Sole power to
    dispose or

    (a) Amount
    (b)
    (i) Sole power to
    direct
    dispose or to
    to direct the
    Reporting
    Beneficially
    Percentage
    vote or to direct
    the
    direct the
    disposition
    Person
    Owned
    of Class
    the vote:
    vote:
    disposition of:
    of:
    Chang-Hai Lin
    4,962,946
    5.89%
    4,962,946
    0
    4,962,946
    0

    * The number of shares are calculated by converting the American Depository Shares, each representing two common shares, into such number of common shares.

    Item 5.
    Ownership of Five Percent or Less of a Class.
       

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ].
       
    Item 6.
    Ownership of more than Five Percent on Behalf of Another Person.

    Not applicable.
       
    Item 7.
    Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.
       
    Not applicable.
       
    Item 8.
    Identification and classification of members of the group.
       
    Not applicable.
       
    Item 9.
    Notice of Dissolution of Group.
       
    Not applicable.
       
    Item 10.
    Certifications.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE


    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


    Dated: February 12, 2021

    Chang-Hai Lin

    /s/ Chang-Hai Lin
     

    Get the next $TLC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TLC

    DatePrice TargetRatingAnalyst
    7/13/2021$11.00 → $7.50Buy → Neutral
    H.C. Wainwright
    7/7/2021Buy → Hold
    Laidlaw
    More analyst ratings

    $TLC
    SEC Filings

    View All

    SEC Form CB/A filed by Taiwan Liposome Company, Ltd. (Amendment)

    CB/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)

    10/14/21 8:58:32 PM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    SEC Form CB/A filed by Taiwan Liposome Company, Ltd. (Amendment)

    CB/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)

    10/8/21 4:00:37 PM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    SEC Form 6-K filed by Taiwan Liposome Company, Ltd.

    6-K - Taiwan Liposome Company, Ltd. (0001722890) (Filer)

    10/8/21 11:56:31 AM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    $TLC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Taiwan Liposome downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Taiwan Liposome from Buy to Neutral and set a new price target of $7.50 from $11.00 previously

    7/13/21 7:44:05 AM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    Taiwan Liposome downgraded by Laidlaw

    Laidlaw downgraded Taiwan Liposome from Buy to Hold

    7/7/21 7:42:46 AM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    $TLC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TLC Announces TLC599 Agreement with Endo

    SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 13, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that it has entered a commercialization agreement with Endo International plc (NASDAQ:ENDP) for rights in the United States to TLC599, a proprietary BioSeizer® sustained release injectable in Phase 3 development for the treatment of osteoarthritis pain. Under the terms of the agreement, signed with Endo's subsidiary Endo Ventures Limited (EVL), TLC will primarily be responsible for the development of the product and EVL will primarily be responsible fo

    6/13/22 6:30:00 AM ET
    $ENDP
    $TLC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals

    TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy

    SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 07, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that detailed results of its TLC599 Phase 2 clinical trial in patients with osteoarthritis of the knee have been published in the peer-reviewed journal Arthritis Research & Therapy. TLC599 is a proprietary BioSeizer® sustained release formulation of dexamethasone sodium phosphate (DSP) intended for the treatment of osteoarthritis pain. The results demonstrated statistically significantly reduced pain scores and oral pain medication use for up to 6 months wit

    3/7/22 4:57:07 AM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    TLC Announces Voluntary Delisting and Deregistration of American Depositary Shares

    This communication does not constitute an offer of any securities for sale or subscription or a solicitation of an offer to purchase or subscribe to any securities in any jurisdiction. The securities to be issued pursuant to the stock swap transaction will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any relevant securities laws of any state or other jurisdiction of the United States. Such securities will be issued in reliance upon the exemption from the registration requirements of the Securities Act provided by Rule 802 thereof. No public offering of such securities will be made in the United States. Such transaction has not been and

    9/8/21 4:40:55 AM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    $TLC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Taiwan Liposome Company, Ltd. (Amendment)

    SC 13D/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)

    1/7/22 8:15:09 PM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13D/A filed by Taiwan Liposome Company, Ltd. (Amendment)

    SC 13D/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)

    11/12/21 6:05:15 AM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13D/A filed by Taiwan Liposome Company, Ltd. (Amendment)

    SC 13D/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)

    10/20/21 4:08:25 PM ET
    $TLC
    Major Pharmaceuticals
    Health Care